Comparison Between Levonorgestrel-Releasing Intrauterine System and Injectable Hormonal Therapy for Persistent Abnormal Uterine Bleeding Following Tubal Ligation

Comparison Between Levonorgestrel-Releasing Intrauterine System and Injectable Hormonal Therapy for Management of Persistent Abnormal Uterine Bleeding Following Tubal Ligation: A Prospective Randomized Controlled Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202608685167118

Enrollment

100

Registered

2026-08-21

Start date

2026-09-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth Urological and Genital Diseases Fertility-female Abnormal uterine blleding , fallopian tubal ligation

Interventions

Levonorgestrel intrauterine system

Injectable Hormonal Therapy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women aged 18–45 years. Previous tubal ligation performed at least 12 months before enrollment. Persistent abnormal uterine bleeding for at least 3 months after tubal ligation. Failure of initial medical treatment. Normal cervical cytology (if applicable). No structural uterine pathology requiring surgery. Willing and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: Pregnancy or suspected pregnancy. Current pelvic inflammatory disease or genital tract infection. Uterine fibroids or endometrial pathology causing abnormal bleeding. Endometrial hyperplasia or malignancy. Congenital uterine anomalies preventing LNG-IUS insertion. Contraindication to levonorgestrel or injectable hormonal therapy. Previous endometrial ablation or hysterectomy. Current use of anticoagulant therapy. Refusal to participate or inability to complete follow-up.

Design outcomes

Primary

Measure	Time frame
Change in menstrual blood loss after treatment, assessed using the Pictorial Blood Loss Assessment Chart (PBAC) scor	—

Secondary

Measure	Time frame
Improvement in hemoglobin concentration (g/dL).	—

Countries

Egypt

Contacts

Public ContactMostafa Elkhot

Resident

mostafalnagar@gmail.com+201008239068

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026